“…In the DIONYSOS trial, dronedarone indeed resulted in a lower incidence of adverse thyroid, neurologic, skin, and ocular effects in patients with atrial fibrillation compared to amiodarone, although it was also less effective (Dobrev and Nattel 2010). However, more recent investigations have suggested that dronedarone does not have a superior safety profile compared to other antiarrhythmic drugs for the treatment of atrial fibrillation (Chatterjee et al 2012;Said et al 2012). In addition, the PALLAS trial was recently halted due to excess mortality in the dronedarone-treated arm, raising concerns about the usefulness of dronedarone (Nattel 2011).…”